Company Overview

Vimta Labs Ltd. (Scrip Code: 524394, NSE: VIMTALABS) presents its Q1 FY27 Investor Presentation. The company is one of India's renowned contract research and testing organizations established in 1984.

Q1 FY27 Financial Performance

Revenue and Profitability

  • Q1 FY27 Revenue: ₹1,129 million, representing 13.2% year-over-year growth from Q1 FY26 revenue of ₹997 million
  • Q1 FY27 EBITDA: ₹411 million (36.4% margin), compared to ₹421 million (37.6% margin) in Q1 FY26, showing a -2.4% decline
  • Q1 FY27 PBT: ₹283 million (25.1% margin), compared to ₹290 million (25.9% margin) in Q1 FY26, showing a -2.4% decline
  • Q1 FY27 PAT: ₹210 million (18.6% margin), compared to ₹211 million (18.9% margin) in Q1 FY26, showing a -0.3% decline
  • Basic EPS: ₹4.7 for Q1 FY27, compared to ₹4.7 in Q1 FY26 (-0.5% change)

Expense Breakdown

  • Material and Testing Costs: ₹226 million (Q1 FY26: ₹224 million)
  • Employee benefits expense: ₹294 million (Q1 FY26: ₹296 million)
  • Other expenses: ₹197 million (Q1 FY26: ₹178 million)
  • Total Expenses: ₹718 million (Q1 FY26: ₹699 million)
  • Finance costs: ₹2 million (Q1 FY26: ₹3 million)
  • Depreciation expense: ₹125 million (Q1 FY26: ₹128 million)
  • Tax: ₹73 million (Q1 FY26: ₹79 million)

Company Business Overview

Infrastructure and Scale

  • Total infrastructure: ~600,000 sq. ft. across multiple locations
  • Employee strength: 1,300+ professionals
  • Total investment: ₹492 million as of 2024
  • FY24 Revenue: ₹3,223 million (from continuing operations, excluding Diagnostic and Pathological services business)

Service Offerings

1. Drug Discovery and Development Services
  • Pharma Analytical services with accreditations from DCA, USFDA, WHO, EMA, and DRAs of Ukraine and Turkey
  • Services include E&L studies, microbiology, stability testing, immunogenicity studies, method development, characterization validations, bioassays, genotoxic impurities, elemental analysis, in vitro studies, physical characterization, dissolution testing
  • Clinical Research services with CDSCO, USFDA, WHO, MHRA, NPRA, and European DRAs approvals
  • Services include BA/BE Studies, bioanalytical, clinical trials (Phase I to IV), clinical end point studies, claim studies
  • Preclinical Research with OECD-GLP, CCSEA, DSIR, AAALAC accreditations
  • Services include comprehensive in vitro, ex vivo and in vivo studies, ADME and PK, IND enabling packages, chronic toxicology, reproductive toxicology, neurotoxicology, immunotoxicology, carcinogenicity, biowaiver studies, ecotoxicology, environmental fate and metabolism studies
2. Biologics - Contract Research & Development Services
  • Small scale Non GMP (R&D) process and product development for DS & DP
  • ICH Guidelines (Q2, Q6B, etc.) compliant services
  • Services include clone screening and selection, cell bank preparation (MCB/WCB), upstream process development, media and feed optimization, downstream process development, protein purification development, chromatography optimization, yield and purity improvement, analytical development, method development and validation, protein characterization, bioreactor process development
3. Food, Agri & Environmental Testing
  • 8 locations: Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida & Kolkata
  • Accreditations: FSSAI, ISO 17025, BIS, APEDA, EIC, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board, MoEF, QCI/NABET, OSHAS 45000
  • Hyderabad Lab is a National Reference Lab for Water & Beverages Testing
  • Mumbai Lab is a National Food Laboratory, operated for FSSAI
  • Services include food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis, new product development support, validations, shelf-life assessments, packaging material testing, nutraceuticals testing, animal feed analysis, agro-chemical testing, post project monitoring, industrial hygiene & indoor air, SIA & hydrogeological studies, EHS audits, hazardous waste study, life cycle assessment, due diligence studies, green audit, metrological studies
4. Electricals & Electronics Testing & Certification
  • 2 locations in Hyderabad
  • Accreditations: NABL ISO 17025, TEC, BIS & NABCB ISO 16025
  • Services include EMI/EMC testing, radio frequency testing, environmental & reliability testing, mechanical & electrical safety testing, performance testing, product certification, CE marking
  • Serves aviation, defence, medical device, telecom, home appliances, toys, industrial & control equipment, consumer electronics, rail & automotive, IT, IOT, physical security products industries

Geographical Presence

The company has a pan-India presence with testing facilities across multiple states.

Management Team

  • Dr. S P Vasireddi: Executive Chairman, founder with 45+ years experience, pioneer of CRO industry in India
  • Harita Vasireddi: Managing Director, nearly 3 decades of experience in TIC/CRO industry, B.Pharm graduate from Mysore University, MBA in Operations Management from Boston College, USA
  • Sreenivas Neerukonda: Executive Director, MBA in Management Information Systems from University of Oklahoma, USA; B.Pharm from Nagpur University
  • Harriman Vungal: Executive Director - Operations, inducted to Board in 1990, appointed Technical Director in 1992, D. Tech in Electronics from Toronto, Canada
  • Siva Kambhampati: Chief Financial Officer, Chartered Accountant, 17+ years experience in engineering and pharmaceutical industries, previously worked at Artson Engineering Ltd. (A TATA Enterprise) as CFO

Growth Strategy and Way Forward

  • Growth momentum in markets for safe & quality drugs, food, electronics & clean environment
  • Core business strategies including capacity expansions, service innovations, penetration into new markets, customer partnerships
  • Operational excellence through hiring right talent, quality & compliance culture, cutting edge technologies
  • Good corporate governance with risk management, listening to customers' needs, continuous learning

Disclaimer and Regulatory Information

  • Presentation contains forward-looking statements subject to risks and uncertainties
  • Financial numbers for FY24 & FY25 are from continuing operations and exclude Diagnostic and Pathological services business
  • CAGR calculations provided for period FY20-FY26